Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen (IMPROVE)
Sponsor: Pfizer
A PHASE4 clinical study on Cystocele and Pelvic Floor Disorders, this trial is completed. The trial is conducted by Pfizer and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE4
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 11 earlier versions
-
Dec 2021 — Jan 2023 [monthly]
Active Not Recruiting PHASE4
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE4
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE4
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Jun 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- University of Alabama at Birmingham
- University of Texas Southwestern Medical Center
- Women and Infants Hospital of Rhode Island
For direct contact, visit the study record on ClinicalTrials.gov .